Haemonetics (HAE) reported fiscal Q3 adjusted earnings Thursday of $1.19 per diluted share, up from $1.04 a year earlier.
Three analysts polled by FactSet expected $1.11.
Net revenue for the quarter ended Dec. 28 was $348.5 million, up from $336.3 million.
Analysts polled by FactSet expected $353 million.
The company narrowed its fiscal year 2025 adjusted EPS to $4.50 to $4.70 from $4.45 to $4.75. Three analysts surveyed by FactSet are looking for $4.35.